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Cryptococcosis is a major opportunistic infection and is one of the leading causes of death in adults 
living with HIV in sub-Saharan Africa. Recent estimates indicate that more than 130,000 people may 
die annually of cryptococcal meningitis in this region. Although complete diagnostic autopsy (CDA) is 
considered the gold standard for determining the cause of death, it is seldom performed in low income 
settings. In this study, a CDA was performed in 284 deceased patients from Mozambique (n = 223) and 
Brazil (n = 61). In depth histopathological and microbiological analyses were carried out in all cases 
dying of cryptococcosis. We determined the cryptococcal species, the molecular and sero-mating 
types and antifungal susceptibility. We also described the organs affected and reviewed the clinical 
presentation and patient management. Among the 284 cases included, 17 fatal cryptococcal infections 
were diagnosed. Cryptococcus was responsible for 16 deaths among the 163 HIV-positive patients 
(10%; 95%CI: 6–15%), including four maternal deaths. One third of the cases corresponded to C. gattii 
(VGI and VGIV molecular types, Bα and Cα strains) and the remaining infections typed were caused by 
C. neoformans var. Grubii (all VNI and Aα strains). The level of pre-mortem clinical suspicion was low 
(7/17, 41%), and 7/17 patients (41%) died within the first 72 hours of admission. Cryptococcosis was 
responsible for a significant proportion of AIDS-related mortality. The clinical diagnosis and patient 
management were inadequate, supporting the need for cryptococcal screening for early detection of 
the disease. This is the first report of the presence of C. gattii infection in Mozambique.
Cryptococcosis is the leading cause of meningitis in adults living with HIV in sub-Saharan Africa1,2. In 2008, the 
number of cryptococcal meningitis (CM) cases in this region was estimated to be 720,000 (range 144,000–1.3 
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million)3. Recent estimates from 2014 indicate that over 160,000 (95%CI 113,600–193,900) cases of CM, includ-
ing more than 130,000 deaths occurred in sub-Saharan Africa4. This significant decrease in the absolute num-
ber of cases from 2008 to 2014 seems to be related to the scale-up of effective antiretroviral therapy (ART)5. 
However, the proportion of AIDS-related deaths due to Cryptococcus remains similar (around 15%), representing 
the second most common cause of AIDS-related mortality in adults, after tuberculosis4. Cryptococcal infection is 
believed to be acquired by inhalation of fungal cells from the environment. In immunocompetent hosts, the path-
ogen can be cleared or establish a latent infection6. In immunocompromised patients, Cryptococcus may induce 
pneumonia and its dissemination to the central nervous system (CNS) causes meningitis, the most severe form 
of the infection, which is fatal without appropriate treatment. In low income countries, the one-year mortality of 
CM, even in HIV-infected patients in care, has been estimated to be as high as 70%4.
Human cryptococcal infections were traditionally attributed to Cryptococcus neoformans until Cryptococcus 
gattii was classified as a distinct species by molecular methods in 20027. Cryptococcus gattii is further divided 
into four molecular types (variety gattii; VGI-VGIV) and little is known about C.gatti infections in Africa, where 
this pathogen has been isolated from both clinical and environmental samples8. Most VGIV strains have been 
described in the southern part of Africa, whereas VGI and VGII strains have been reported in central Africa8. C. 
gattii infections were thought to occur mainly in the tropics9 until 2004, when an outbreak of C. gattii in North 
America was recognized10. This outbreak was caused by VGII strains and included the emergence of hyperviru-
lent variants11. Current knowledge on the epidemiology and clinical presentation of C. neoformans infection is 
clearly greater than that related to C. gattii. C. neoformans infections occur predominantly in people infected with 
HIV or with other immunocompromising conditions, whereas C. gattii infections have been mainly described 
in apparently immunocompetent patients9. Autopsy findings reveal that the CNS and the lungs are the organs 
most frequently affected in disseminated infections12,13, which may also affect multiple organs, especially in 
HIV-infected patients14. However, reported autopsy series do not usually include cryptococcal species identifica-
tion, and therefore, knowledge regarding the histopathology of C. gattii remains limited.
In the present study, we determined the Cryptococcus-associated mortality of a series of 284 autopsies per-
formed in two hospitals located in high prevalence HIV areas, Mozambique in sub-Saharan Africa and the 
Brazilian Amazonia. We also analysed the clinical presentation, management, and histopathological and micro-
biological findings of 17 cases of fatal cryptococcal infection.
Methods
study setting and design. An observational study was performed at the Department of Pathology of the 
Maputo Central Hospital in Maputo, Mozambique and at the Fundação de Medicina Tropical Doutor Heitor Vieira 
Dourado, in Manaus, Western Brazilian Amazon. The study was approved by the Comissão Nacional de Ética 
em Pesquisa - CONEP (Brazil; Ref. 1.074.304), the Clinical Research Ethics Committee of the Hospital Clinic 
of Barcelona (Spain; File 2013/8677) and National Bioethics Committee of Mozambique (Mozambique; Ref. 
342/CNBS/13), which deemed verbal consent sufficient in this study. All research was performed in accordance 
with guidelines and regulations of the Montreal Statement on Research Integrity in Cross-Boundary Research 
Collaborations, and the Singapore Statement on Research Integrity.
From November 2013 to March 2015, complete diagnostic autopsies (CDAs) were performed in 284 deceased 
patients in the two study sites. Two hundred twenty-three cases were recruited from Mozambique: 169 were 
adults over 15 years of age (112 women, 57 of whom were maternal deaths, i. e., women dying during pregnancy, 
partum, post-partum or within 42 days of termination of pregnancy15), and 54 were children from 1 month to 
15 years of age (37 males and 17 females). Sixty-one cases were recruited from Brazil: 59 adults (38 males and 
21 females, including one maternal death) and two children. A description of the study design and inclusion 
criteria for the cases has been published elsewhere16–18. All cases fulfilling the inclusion criteria were included in 
the study; these were (1) a CDA requested by the clinician as part of the medical evaluation of the patient and; 
(2) a verbal informed consent to perform the autopsy given by the relatives. Traumatic deaths were excluded. A 
member of the study staff was tasked with liaising with the families in cases of deaths occurring in the pediatric 
department, but only after the clinicians had asked for consent for postmortem examination17. All the clinical 
records available regarding admission preceding death of each patient were reviewed and the clinical data were 
collected in a standardized manner.
Autopsy procedures and determination of the cause of death. The autopsy procedures and a 
description of the pathological and microbiological methods used have been reported elsewhere19,20 and for 
Briefly, samples of blood, cerebrospinal fluid (CSF), bone marrow and key organs such as the liver, lungs, CNS, 
spleen and kidneys, as well as uterus in all women of reproductive age were collected for histopathological and 
microbiological analysis. The microbiological methods included universal screening for relevant pathogens (e.g. 
HIV, viral hepatitis, tuberculosis, malaria) and bacterial/fungal culture of autopsy samples, targeted screen-
ing depending on the patient’s condition (i.e. screening for Cryptococcus, Toxoplasma gondii and Pneumocystis 
jirovecii in HIV-infected cases), and additional specific testing according to the histopathological findings. 
Following the analysis of the CDA samples, a panel composed of a pathologist, a microbiologist, and a clinician 
with expertise in infectious diseases and epidemiology evaluated all the data (including the clinical information) 
and assigned the final cause of death.
Laboratory methods. All cases in which the cause of death was assigned to a cryptococcal infection were 
further characterized. The histological evaluation included periodic acid–Schiff staining (PAS) of the samples 
of both lungs, CNS, bone marrow, spleen, liver, kidney and uterus, as well as Grocott-Gomorimethenamine sil-
ver staining in all CNS samples. Microbiological evaluation included a specific real time PCR for Cryptococcus 
spp.21, which was performed in the samples of both lungs, CNS, bone marrow, spleen, liver and uterus. PCR cycle 
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threshold values >38 were considered negative. Plasma and CSF samples were tested by both real time PCR and 
the Cryptococcus antigen (CrAg) lateral flow assay (LFA) (IMMY Inc., Norman, Oklahoma). Discrimination 
between C. neoformans var. grubii, C. neoformans var. neoformans, and C. gattii was achieved by amplification of 
the rRNA intergenic spacer (IGS) region, followed by forward and reverse Sanger sequencing of the amplicons. 
Identities of the cryptococcal species were assigned based on a >98% match to the IGS sequence of a Cryptococcus 
reference strain (C. gattii: CBS 6289, ATCC MYA-4561, CBS 6955, ATCC MYA-4563; C. neoformans var. gru-
bii: ATCC MYA-4564, ATCC MYA-4565 and C. neoformans var. neoformans: ATCC MYA-4567) as described 
previously22.
Cryptococcal strains isolated from the cultures of the autopsy samples underwent a consensus multi-locus 
sequence typing scheme for C. neoformans and C. gattii23. In addition, the sero-mating type of these strains 
was determined by multiplex PCR as described previously24,25. An anti-fungogram was performed for each 
strain using the Sensititre® YeastOne® susceptibility plate (TREK Diagnostic Systems, Thermo Fisher Scientific, 
Oakwood Village, USA).
statistical methods. Descriptive analysis was performed using univariate statistics with means and stand-
ard deviations for continuous variables and frequency distributions for categorical variables. All analyses, data 
manipulation, and implementations were done using Stata MP version 15 (Stata, College Station, TX, USA).
Results
Mortality due to cryptococcal infections. Among the 284 deceased patients included in this study, 163 
(57%) tested positive for HIV, and a total of 17 (6%) fatal cryptococcal infections were confirmed in the CDA. 
All the deaths except one occurred in HIV-infected cases. Among the HIV-infected cases, cryptococcosis was 
responsible for 16 deaths (10%; 95% confidence interval [CI]: 6–15%). Among the Mozambican adults, 109 out 
of 169 (64%) were HIV-infected, and 11 died of fatal cryptococcal infection (10%). Four of these cases were 
maternal deaths (three pregnant women and one in the puerperal period), accounting for 11% of the 36 maternal 
deaths occurring in HIV-infected women. None of the 17 HIV-positive children over one month of age had cryp-
tococcal infection. Thirty-seven out of the 61 (61%) patients from Brazil were HIV-infected, and Cryptococcus 
was responsible for five of these deaths (13%). The only death caused by Cryptococcus in an HIV-negative patient 
occurred in a six-year-old child (infected with C. gattii).
Clinical presentation and management of fatal cryptococcal infections. The demographic fea-
tures, HIV status, clinical presentation and management of the 17 patients with fatal cryptococcal infection are 
summarized in Table 1. The median age was 34 years (range 6–44 years); 11 cases (65%) were men. In 13 out of 
the 16 (81%) HIV-infected patients, a positive HIV test result was reported in the clinical records and was appar-
ently unknown by the clinician in the other 3 cases. Four out of the 16 (25%) HIV-infected patients were on ART, 
but the duration of ART was only reported in one case.
Headache was the most common symptom (13 patients, 76%), followed by fever and vomiting (eight cases 
each, 47%). Upon admission to hospital, eight patients (47%) were confused and/or agitated, two patients (12%) 
were lethargic, and another two (12%) were fully comatose. Meningeal signs were detected in seven patients 
(41%). The mean time from admission to death was 9.3 days (95%CI: 2.4–16.2). Cryptococcal infection was 
considered the first clinical diagnostic option in only 4/17 (23%) of the confirmed cases, whereas it was included 
in the differential diagnosis in eight patients (47%). Antifungal treatment (fluconazole or Amphotericin B) had 
been prescribed to seven patients but to only five of the clinically suspected cases. Seven of the patients (41%) 
died within 72 hours of admission, and 12 out of the 16 HIV-positive patients (75%) died within one week of 
admission.
The clinical records of the remaining 267 cases included in this study were reviewed for clinical diagnosis of 
cryptococcal infection. Among these, three HIV-infected patients were clinically diagnosed with cryptococcal 
meningitis, but no evidence of cryptococcal infection was found in the autopsy (the cause of death was identified 
as toxoplasmosis in two cases and tuberculosis in one case).
Histopathological and microbiological analysis of the fatal cryptococcal infections. Table 2 
shows the final cause of death, the cryptococcal species, other associated diagnoses identified in the CDA, as well 
as the results of the PAS staining, Cryptococcus real time PCR and CrAg test in the different samples analysed. 
Identification of the cryptococcal species was successful in 15 out of the 17 cases. In two cases, the tissue samples 
provided insufficient DNA to perform IGS amplification and sequencing. Interestingly, among the 15 cases iden-
tified, five (33%) were C. gattii whereas the remaining cases (66.6%) were C. neoformans var. grubii.
Twelve of the 17 cases (70%) were diagnosed as disseminated infections and the remaining 5(30%) as menin-
goencephalitis.The CNS was affected in all 17 cases. The following were the most affected organs (PAS and/
or PCR positive): the lungs (88%), spleen (76%), liver (71%), bone marrow (59%) and kidney (47%). In addi-
tion, in five out of six (83%) deceased women, the pathogen was detected in uterus samples, and in one case it 
was detected in the placenta. Cryptococcus was found in more than 5 different samples in 11 patients (65% of 
the cases). More organs were affected in C. neoformans var. grubii than in C. gattii infections (mean of 6.2 vs. 
2.8 organs positive by PAS staining), but no specific histopathological differences were observed between the 
two Cryptococcus species. Molecular testing expanded the detection of Cryptococcus in 14 additional tissues that 
were negative for PAS staining. In contrast, two tissue samples were positive for PAS staining but negative by 
real time PCR. Periodic acid–Schiff staining and Grocott-Gomorimethenamine silver staining showed identical 
results. Representative histopathological images of different affected tissues are shown in Fig. 1. Cryptococcus was 
detected by PCR in CSF and plasma in 80% and 47% of the cases tested, respectively. All plasma and CSF samples 
tested for CrAg LFA were positive. Co-infections with other AIDS-related pathogens or AIDS-defining illnesses 










































































Cephalosporin, acyclovir Fluconazole 2.9 NA







Cephalosporin No 1.1 NA
5 36; M;MOZ NA Positive 1,180
Headache, 








disease, liver failure 
unspecified
Co-trimoxazole, Cephalosporin Fluconazole 21.9 NA






None No 4.4 No






Cephalosporin No 0.4 Yes














metronidazole, albendazole No 0.3 NA








Co-trimoxazole, cephalosporin Amphotericin B 3.2 No
10 21; F;MOZ Yes Positive >100** Dyspnea
Pneumocystosis, 







metronidazole No 0.9 NA











Co-trimoxazole, cephalosporin Amphotericin B 2.8 NA







of labor and delivery
Data not available No 0.0 Yes
Continued
5Scientific RepoRts |          (2019) 9:7493  | https://doi.org/10.1038/s41598-019-43941-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
(Mycobacterium tuberculosis, cytomegalovirus, esophageal candidiasis, Toxoplasma gondii, and Histoplasma cap-
sulatum) were detected in five cases.
Cryptococcus strain characterization. Eight strains were isolated by culture, seven from the CSF and one 
from the blood. The molecular characterization and antifungal susceptibility of the cryptococcal strains isolated 
are shown in Table 3. All C. neoformans var. grubii corresponded to the VNI molecular type, whereas two differ-
ent genotypes, VGI and VGIV, were identified in the two C. gattii isolates. Sero-mating type Aα was found in all 
the C. neoformans isolates. Bα and Cα strains were found among the C. gattii strains.
Minimum inhibitory concentrations (MICs) of a variety of antifungal agents were determined (Table 3). All 
triazole antifungal agents (fluconazole, voriconazole, itraconazole and posaconazole) had MICs less than or equal 
to the defined epidemiological cut-off values (ECVs)26. One isolate showed a MIC to flucytosine (16 µg/mL), one 
dilution higher than the ECV (8 µg/mL). Although all the isolates presented a MIC ≤ 1 µg/mL to amphotericin, 
the MICs of three C. neoformans molecular type VNI (1 µg/mL) and two C. gattii (1 µg/mL) were one dilution 
higher than the defined ECVs (0.5 µg/mL)27.
Discussion
In a large series of nearly 300 autopsies, we performed a thorough histopathological and microbiological analysis 
of 17 fatal cryptococcal infections, 12 from Mozambique and five from Brazil. Several studies on cryptococcal 
infection have been carried out in Brazil14,28, but there are no data from Mozambique. Indeed, despite being a 
highly endemic area for HIV, a literature search was unable to find reports describing the burden of this pathogen 
in this country. Thus, to our knowledge, this is the largest autopsy-based description of fatal cryptococcal infec-
tions in Mozambique. Interestingly, albeit being Maputo and Manaus two sites from different countries in terms 
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Table 1. Clinical characteristics and management of fatal cryptococcal infections. Clinical diagnoses are listed 
in the order of differential diagnoses included in the clinical charts. Cryptococcosis is identified in bold, when 
considered in the list of diagnoses. *As written in the clinical charts by clinicians in charge of patients; M: male; 
F: female; MOZ: Maputo-Mozambique; BRA: Manaus-Brazil; ART: antiretroviral therapy; NA: not applicable. 
**The precise quantification was not possible due to the presence of PCR inhibitors in the plasma, which 
inhibited the amplification of the internal control of the assay. A minimal viral load was inferred from samples 
with quantifiable viral loads showing a similar cycle threshold for HIV-1 in the PCR assay; NT: not tested due to 
insufficient amount of sample.
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Table 2. Causes of death, histopathological and microbiological findings. CNS: Central Nervous system; CSF: 
cerebrospinal fluid; CoD: cause of death; TND: Target Not Detected; NT: not tested due to insufficient amount 
of sample; NA: Not applicable; PAS: Periodic acid–Schiff staining; *PAS positive in placental tissue; PCR: Cycle 
threshold of a specific real time PCR for Cryptococcus is indicated; **no kidney samples for PCR testing were 
collected.
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patients (over 60%) and the Cryptococcus associated mortality in HIV positive patients. In this study Cryptococcus 
was responsible for 10% of the deaths among HIV-infected patients. This figure is in agreement with current esti-
mates of 15% of AIDS-related deaths due to CM4. Although treatment with ART has led to an important reduc-
tion in the mortality of HIV-infected patients in sub-Saharan Africa, at present, cryptococcal-related death seems 
to remain similar to 2008 estimates. In agreement with other autopsy series, HIV-associated cryptococcosis is fre-
quently presented as a disseminated infection14,28. Other studies have reported that up to one half of cryptococcal 
Figure 1. Cryptococcal disseminated infections: (A) Cryptococcus neoformans infecting the central nervous 
system (hematoxylin and eosin, 400×). (A’) Cryptococcus gattii infecting the central nervous system 
(hematoxylin and eosin, 400×); abundant capsulated yeasts growing extensively in the perivascular spaces, 
which become cystically dilated; virtually no inflammatory reaction is seen. (B) Cryptococcus neoformans 
infecting the lung (hematoxylin and eosin, 100×); (B’) Cryptococcus gattii infecting the lung (hematoxylin 
and eosin, 100×); abundant capsulated yeasts growing extensively in the alveolar spaces; scant inflammatory 
reaction is seen. (C) Cryptococcus neoformans infecting the placenta (hematoxylin and eosin, 400×); (C’) 








Minimum inhibitory concentration (µg/mL)
Amphotericin B Fluconazole Voriconazole Itraconazole Posaconazole Flucytosine
2 CSF Cryptococcus neoformans var. grubii VNI A α 1 8 0.12 0.12 0.25 8
3 CSF Cryptococcus neoformans var. grubii VNI A α 1 4 0.06 0.03 0.06 4
4 CSF Cryptococcus gattii VGI B α 1 4 0.12 0.03 0.06 1
7 Blood Cryptococcus gattii VGIV C α 1 16 0.25 0.06 0.06 4
8 CSF Cryptococcus neoformans var. grubii VNI A α 1 4 0.06 0.06 0.06 4
9 CSF Cryptococcus neoformans var. grubii VNI A α 0.5 8 0.06 0.03 0.06 16
10 CSF Cryptococcus neoformans var. Grubii VNI A α 1 8 0.06 0.03 0.12 4
11 CSF Cryptococcus neoformans var. Grubii VNI A α 0.5 8 0.06 0.06 0.12 4
Table 3. Molecular characterization and antifungal susceptibility of isolated cryptococcal strains. CSF: 
cerebrospinal fluid.
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infections are detected in HIV-infected patients receiving ART29. In our series, only a quarter of the HIV-positive 
cases (4/16) were under ART. Unfortunately, the duration of ART was only available in one case. This case had a 
6-year history of ART and a high viral load, and therefore, likely represents a treatment failure or defaulted. Other 
explanations for cryptococcal infection in patients receiving adequate ART include recent treatment initiation in 
patients with very low CD4 counts (late HIV diagnosis) and cases of immune reconstitution inflammatory syn-
drome30, which might also have been present in our series. Despite progress in ART deployment in sub-Saharan 
Africa, close to 50% of HIV-infected patients continue presenting to health facilities with advanced HIV dis-
ease31, thereby being at high risk of cryptococcal infection and death. In this regard, the CrAg can be detected 
up to three weeks before the onset of CM symptoms32 and therefore, screening of asymptomatic HIV patients 
followed by preemptive antifungal treatment might identify patients at risk of developing the disease and contrib-
ute to reducing CM-related mortality33,34. In the present study, most cases died within the first week of hospital 
admission, which is in contrast with other series reporting a mean of two weeks between admission and death35. 
Several factors might have contributed to the rapid fatal outcome in our series. Firstly, the low frequency of clin-
ical suspicion of cryptococcosis may explain the absence of prescribed antifungal treatment in more than half of 
the patients. On the other hand, some patients may have presented to the hospital with advanced severe stages 
of cryptococcal infection, considering that seven died within three days of admission (four within 24 hours). 
The longest hospital admission involved a child who died of C. gattii meningitis about two months after hospital 
admission. C. gattii infections are rare in children, and as in the child in this series, the infection often occurs in 
previously healthy children and presents with CNS involvement9. The little knowledge available about C. gattii in 
sub-Saharan Africa has been obtained from studies performed in South Africa. Interestingly, in our study four 
out of the 12 cryptococcal infections (25%) from Mozambique were due to C. gattii infections. Although the 
numbers are small and should be interpreted with caution, these data contrast with previous findings from South 
Africa, where C. gattii represented only 2.4% of the cryptococcal strains isolated over a two-year period36. C. gattii 
infections have mainly been reported in immunocompetent hosts, until studies from South Africa revealed that 
it affects immunocompromised patients as well37,38. It has been reported that the VGI C. gattii molecular type is 
much more likely to affect immunocompetent patients than VGIV9. However, both genotypes were detected in 
HIV-infected patients in our study. All strains of C. neoformans var. grubii were molecular type VNI and pos-
sessed the sero-mating type Aα, similar to most of the strains described in South Africa. To our knowledge, this 
is the first report of C. gattii in Mozambique, and the Bα and Cα types detected have been previously reported in 
South Africa39,40. Although no clinical breakpoints are available for Cryptococcus, antifungal susceptibility testing 
did not suggest clear resistance patterns, with only MICs one dilution above the ECV being found.
A few isolated autopsy reports of fatal C. gattii infections in immunocompetent patients have been reported41, 
which may be explained by the fact that the distinction between C. gattii and C. neoformans was not performed 
in many studies. Although the numbers are small, dissemination of the infection seems to be less intense in 
HIV-infected patients with C. gattii compared to C. neoformans. Larger studies are needed to better assess 
the histopathological features of C. gattii in HIV-infected patients. Moreover, studies based on post-mortem 
examinations should be performed to better assess the mortality attributable to specific pathogens in low- and 
middle-income countries. Accurate mortality data can then impact public health policies, for example, guiding 
prophylactic and treatment schemes for infectious diseases.
In conclusion, our study highlights the substantial mortality associated with cryptococcal infections among 
HIV-infected patients, supporting current recommendations42 of CrAg screening and preemptive therapy, which 
is even more relevant in settings in which insufficient pre-mortem clinical suspicion is given to this highly preva-
lent and life-threatening opportunistic infection.
ethics approval and consent to participate. The study protocol received approval of the National 
Mozambican Ethics Committee (ref.342/CNBS/13) and the Ethics Committee of the Hospital Clinic of Barcelona 
(Spain; approved, File 2013/8677). MIA and CDA procedures were only conducted after verbal informed consent 
was provided by the relatives.
Data Availability
All relevant data are within the paper. Any additional data use and transfer is monitored by ISGlobal’s Data Man-
agement and Biostatistics Unit (contact e-mail: ubioesdm@isglobal.org).
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